CytoDyn Income Statement

Financials in millions USD. Fiscal year is June - May.

Millions USD. Fiscal year is Jun - May.

Year	2023	2022	2021	2020	2019	2018 - 2004
Revenue	0	0.27	0	0	0	Upgrade
Cost of Revenue	0.18	0.05	1.8	2.03	1.25	Upgrade
Gross Profit	-0.18	0.21	-1.8	-2.03	-1.25	Upgrade
Selling, General & Admin	17.14	44.3	34.32	19.97	12.12	Upgrade
Research & Development	2.63	27.04	58.43	52.64	42.49	Upgrade
Other Operating Expenses	-20.63	0.78	1.8	2.03	1.25	Upgrade
Operating Expenses	40.4	72.13	94.55	74.65	55.85	Upgrade
Operating Income	-40.58	-71.91	-104.6	-74.65	-55.85	Upgrade
Interest Income	25.19	24.18	0	0.01	0	Upgrade
Interest Expense	25.19	52.45	19.34	16.88	2.85	Upgrade
Other Expense / Income	26.25	110.64	30.74	32.88	0.31	Upgrade
Pretax Income	-79.82	-210.82	-154.67	-124.4	-59.01	Upgrade
Income Tax	12.99	77.34	19.34	17.38	-2.83	Upgrade
Net Income	-79.82	-288.16	-174.02	-141.78	-56.19	Upgrade
Shares Outstanding (Basic)	837	677	588	421	272	Upgrade
Shares Outstanding (Diluted)	837	677	588	421	272	Upgrade
Shares Change	23.58%	15.20%	39.54%	54.78%	55.55%	Upgrade
EPS (Basic)	-0.10	-0.43	-0.30	-0.34	-0.21	Upgrade
EPS (Diluted)	-0.10	-0.43	-0.30	-0.34	-0.21	Upgrade
Free Cash Flow	-25.11	-77.72	-117.7	-68.84	-50.51	Upgrade
Free Cash Flow Per Share	-0.03	-0.11	-0.20	-0.16	-0.19	Upgrade
Gross Margin	-	80.08%	-	-	-	Upgrade
Operating Margin	-	-27035.34%	-	-	-	Upgrade
Profit Margin	-	-108331.95%	-	-	-	Upgrade
Free Cash Flow Margin	-	-29219.17%	-	-	-	Upgrade
EBITDA	-40.4	-80.25	-92.96	-73.45	-55.06	Upgrade
EBITDA Margin	-	-30168.80%	-	-	-	Upgrade
Depreciation & Amortization	0.18	0.78	1.8	2.03	1.25	Upgrade
EBIT	-40.58	-81.03	-94.76	-75.48	-56.31	Upgrade
EBIT Margin	-	-30462.41%	-	-	-	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.